spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Zevalin 

 HSMN NewsFeed - 7 Nov 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 2 Apr 2019
CASI Pharmaceuticals Announces the Appointment of Wei-Wu He, Ph.D., Executive Chairman, to the Role of Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2018
CASI Pharmaceuticals Announces Appointment of President to its China Operations to Lead Commercialization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2018
CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2018
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Sep 2018
CASI Pharmaceuticals Announces $48.5 Million Private Placement
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Mar 2018
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2015
Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA(TM) (melphalan) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2015
CASI Pharmaceuticals to Raise $25.1 Million in Private Placement of Common Stock and Warrants
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Aug 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Mar 2015
CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Apr 2014
Inovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 17 Jul 2013
Spectrum Pharmaceuticals Acquires Talon Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Jun 2013
Spectrum Pharmaceuticals Further Strengthens Management; Announces Appointment of Kurt Gustafson as Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2013
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Jan 2013
Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2013
MEI Pharma Announces Retirement Of Chairman Bryan Williams From Board Of Directors And Appointment Of Christine White As Lead Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2012
Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2012
Spectrum Pharmaceuticals Appoints Industry Veteran, Former Amgen Executive Joseph Turgeon, as Senior Vice President Sales & Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Sep 2012
Spectrum Pharmaceuticals Appoints Industry Veteran and Former Senior Amgen Executive, Ken Keller, as Executive Vice President, Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2012
Spectrum Pharmaceuticals Launches a Broad-based FUSILEV(R) Marketing Campaign; Increases Sales Force Footprint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2012
Spectrum Pharmaceuticals Strengthens Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Spectrum Pharmaceuticals to Develop Biosimilar Rituximab
Biopharmaceuticals Oncology Generics
 HSMN NewsFeed - 12 Oct 2010
Spectrum Pharmaceuticals Announces Appointment of Brett L. Scott as Senior Vice President and Acting Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jul 2010
Spectrum Pharmaceuticals Appoints George Tidmarsh, M.D., Ph.D, as Senior Vice President, Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2010
BioVex Appoints Steven Kelly as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jun 2010
Spectrum Pharmaceuticals Appoints James E. Shields as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Oct 2008
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Sep 2008
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2008
Veteran Drug Industry Executive to Become President of CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 8 Nov 2007
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Aug 2007
Vical Names Andrew de Guttadauro Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology
 HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2007
Oncologic Appoints Stephen T. Isaacs as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 31

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 31 additional stories matching:
Zevalin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.